[시장보고서]고활성 원료의약품(HPAPI) 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 제조업체 유형별, 약제 유형별, 용도별, 지역별, 부문별 예측(2026-2033년)

고활성 원료의약품(HPAPI) 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 제조업체 유형별, 약제 유형별, 용도별, 지역별, 부문별 예측(2026-2033년)

High Potency Active Pharmaceutical Ingredients Market Size, Share & Trends Analysis Report By Product, By Manufacturer Type, By Drug Type, By Application, By Region, And Segment Forecasts, 2026 - 2033

상품코드 : 1941791

리서치사 : Grand View Research

발행일 : 2026년 01월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,981,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,491,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,510,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

HPAPI 시장 요약

세계의 HPAPI(고활성 원료의약품) 시장 규모는 2025년에 298억 7,000만 달러로 추정되며, 2033년까지 482억 9,000만 달러에 달할 것으로 예측됩니다.

2026-2033년 연평균 복합 성장률(CAGR) 6.2%를 나타낼 것으로 예측됩니다. 이러한 성장은 주로 암 및 기타 만성질환의 유병률 증가, 표적치료제 및 항암제 채택 증가, 항체약물접합체 및 세포독성 화합물과 같은 고활성 분자 개발 파이프라인의 확대에 의해 주도되고 있습니다.

또한 HPAPI 제조 전문 CDMO에 대한 아웃소싱 증가, 고밀폐 제조 시설에 대한 지속적인 투자, 경험이 풍부한 기업을 우대하는 엄격한 규제 요건은 시장 확대를 더욱 촉진하고 있습니다.

암 및 기타 복잡한 만성질환의 발생률 증가는 고활성 원료의약품 시장을 촉진하는 핵심적인 요인으로 작용했습니다. 현대의 종양 치료는 매우 낮은 농도로 치료 효과를 달성하는 고활성 분자에 대한 의존도가 높아지고 있으며, 이는 표적 약물의 작용과 환자 예후를 개선하는 데 도움을 주고 있습니다. 제약 연구 파이프라인은 여러 암종의 미충족 수요에 대응하기 위해 지속적으로 고활성 분자를 우선 개발 대상으로 삼고 있습니다. HPAPI는 임상적 효과를 유지하면서 용량을 줄이는 데 필수적이며, 정밀한 생물학적 상호작용을 필요로 하는 첨단 치료법에 대한 관심이 높아지는 추세에 부합합니다. 예를 들어 2025년 1월 포르파마 API가 발표한 바에 따르면 2050년까지 전 세계 암 환자 수가 61% 증가할 것으로 예상되며, 2023년 신규 출시되는 활성 성분의 25%가 종양학 분야로, 임상 개발부터 상업 생산까지 고활성 의약품 성분에 대한 지속적인 수요를 지원하고 있습니다. 고활성 의약품 성분에 대한 지속적인 수요가 지원되었습니다.

표적치료제 및 첨단 약물의 채택 확대가 HPAPI 시장 성장에 크게 기여했습니다. 신약개발 전략은 정밀의료에 집중하는 경향이 강해지면서 특정 작용기전을 가진 고활성 화합물이 필수적으로 요구되고 있습니다. 항체약물접합체(ADC), 세포독성 약물, 호르몬 요법은 투여 효율과 치료의 일관성을 향상시키면서 제어된 치료 효과를 발휘하기 위해 고효능 성분에 의존하고 있습니다. 제약 혁신가들은 부작용을 관리하면서 효능을 높이기 위해 HPAPI를 우선적으로 채택하고 있으며, 의약품 파이프라인에서 고효능 분자로의 전환을 가속화하고 있습니다. 예를 들어 2025년 11월 DCAT 밸류체인 인사이트에 따르면 항체약물접합체(ADC) 전문 수탁 서비스 프로바이더의 약 70%가 항체 및/또는 HPAPI 세포독성 페이로드 제조 서비스를 제공하고 있으며, HPAPI 페이로드는 ADC 수탁제조 밸류체인의 약 20%를 차지합니다. HPAPI 페이로드는 ADC 수탁제조 밸류체인의 약 20%를 차지하고 있습니다. 이는 첨단 치료제 개발에서 고활성 성분의 역할이 증가하고 있음을 보여줍니다.

위탁개발생산기관(CDMO)에 대한 의존도가 높아진 것도 시장 확대의 주요 촉진요인 중 하나였습니다. HPAPI 제조는 첨단 봉쇄 시스템과 전문적인 기술 지식이 필요한 복잡한 공정을 수반하므로 많은 제약사들은 안전성과 운영상의 복잡성을 관리하기 위해 생산을 아웃소싱하고 있습니다. CDMO는 통합적인 합성, 제형, 상업적 공급 서비스를 제공하면서 확장성을 높이고 개발 기간을 단축하기 위해 고밀폐 인프라에 대한 투자를 지속하고 있습니다. 예를 들어 Pharmaceutical Technology지 2025년 12월호에 따르면 여러 CDMO가 HPAPI 생산 능력 확대를 위해 다음과 같은 중점 투자를 단행했다: HPAPI 및 ADC 생산에 특화된 9,000만 달러 규모의 확장 계획, 2025년 초에 새로운 2025년 초 CGMP 준수 분석 시험실 개설, 2024년 5월부터 2025년 1월까지 HPAPI 생산능력 추가 증설 계획이 발표되었습니다. 이는 아웃소싱 수요 증가에 따른 지속적인 인프라 투자를 강조하는 것입니다.

영문목차

HPAPI Market Summary

The global high potency active pharmaceutical ingredients (HPAPI) market size was estimated at USD 29.87 billion in 2025 and is projected to reach USD 48.29 billion by 2033, growing at a CAGR of 6.2% from 2026 to 2033. This growth is primarily driven by the rising prevalence of cancer and other chronic diseases, increasing adoption of targeted therapies and oncology drugs, and the expanding pipeline of highly potent molecules such as antibody drug conjugates and cytotoxic compounds.

In addition, growing outsourcing of HPAPI manufacturing to specialized CDMOs, continuous investments in high-containment manufacturing facilities, and stringent regulatory requirements that favor experienced players are further supporting market expansion.

The rising incidence of cancer and other complex chronic conditions was a central factor driving the high potency active pharmaceutical ingredients market. Modern oncology treatment increasingly depended on highly potent molecules that achieved therapeutic effects at extremely low concentrations, supporting targeted drug action and improved patient outcomes. Pharmaceutical research pipelines continued to prioritize potent molecules to address unmet medical needs across multiple cancer types. HPAPIs were essential for reducing dosage volumes while maintaining clinical effectiveness, aligning with the growing emphasis on advanced therapies requiring precise biological interaction. For instance, January 2025, Polpharma API reported that global cancer cases were expected to increase by 61 percent by 2050, and that oncology accounted for 25 newly launched active substances in 2023, reinforcing sustained demand for highly potent active pharmaceutical ingredients across clinical development and commercial production.

The growing adoption of targeted therapies and advanced drug modalities significantly contributed to HPAPI market growth. Drug development strategies increasingly focused on precision medicine, which relied on potent compounds with specific mechanisms of action. Antibody drug conjugates, cytotoxic agents, and hormonal therapies depended on high potency ingredients to deliver controlled therapeutic effects while improving dosing efficiency and treatment consistency. Pharmaceutical innovators favored HPAPIs to enhance efficacy while managing side effects, accelerating the shift toward higher potency molecules in drug pipelines. For instance, November 2025, DCAT Value Chain Insights reported that approximately 70 percent of ADC-focused contract service providers offered manufacturing services for antibodies and or HPAPI cytotoxic payloads, and that HPAPI payloads represented about 20 percent of the ADC contract manufacturing value chain, underscoring the increasing role of potent ingredients in advanced therapeutic development.

The increasing dependence on contract development and manufacturing organizations was another major driver of market expansion. HPAPI manufacturing involved complex processes requiring advanced containment systems and specialized technical expertise, leading many pharmaceutical companies to outsource production to manage safety and operational complexity. CDMOs continued to invest in high containment infrastructure to improve scalability and accelerate development timelines while offering integrated synthesis, formulation, and commercial supply services. For instance, December 2025, Pharmaceutical Technology reported that multiple CDMOs expanded HPAPI capabilities through targeted investments, including a USD 90 million expansion focused on HPAPI and ADC manufacturing, the launch of new CGMP analytical testing laboratories in early 2025, and additional HPAPI capacity upgrades announced between January 2025 and May 2024, highlighting sustained infrastructure investment driven by growing outsourcing demand.

Global High Potency Active Pharmaceutical Ingredients Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global high potency active pharmaceutical ingredients market report based on product, manufacturer type, drug type, application, and region:

Product Outlook (Revenue, USD Million, 2021 - 2033)
Synthetic
Biotech
Manufacturer Type Outlook (Revenue, USD Million, 2021 - 2033)
In-house
Outsourced
Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
Innovative
Generic
Application Outlook (Revenue, USD Million, 2021 - 2033)
Oncology
Hormonal
Glaucoma
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. High Potency Active Pharmaceutical Ingredients Market: Methodology and Scope

1.1 Market Segmentation
- 1.1.1 Segment Scope
- 1.1.2 Regional Scope
- 1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
- 1.3.1 Purchased Database
- 1.3.2 Gvr's Internal Database
- 1.3.3 Secondary Sources
- 1.3.4 Primary Research
- 1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
- 1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
- 1.6.1 Commodity Flow Analysis
  - 1.6.1.1 Approach 1: Commodity Flow Approach
  - 1.6.1.2 Approach 2: Country wise market estimation using bottom up approach
  - 1.6.1.3 Approach 2: Country wise market estimation using top down approach
1.7 Global Market: CAGR Calculation
1.8 List of Secondary Sources
1.9 Objectives
- 1.9.1 Objective 1:
- 1.9.2 Objective 2:

Chapter 2. High Potency Active Pharmaceutical Ingredients Market: Executive Summary

2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot

Chapter 3. High Potency Active Pharmaceutical Ingredients Market: Variables, Trends & Scope

3.1 Market Lineage Outlook
- 3.1.1 Parent Market Lineage Outlook
- 3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
- 3.3.1 Market Driver Analysis
  - 3.3.1.1 Rising prevalence of cancer
  - 3.3.1.2 Growth of targeted therapies
  - 3.3.1.3 Increasing application of HPAPI
- 3.3.2 Market Restraint Analysis
  - 3.3.2.1 Large investments and very stringent safety and handling specifications associated with production of HPAPI
3.4 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.5 Industry Analysis - Porter's
3.6 Reimbursement & Regulatory Scenario
3.7 Major Deals & Strategic Alliances
- 3.7.1 New Product Launch
- 3.7.2 Acquisition
- 3.7.3 Expansion
- 3.7.4 Partnerships
- 3.7.5 Marketing & Promotions

Chapter 4. High Potency Active Pharmaceutical Ingredients Market: Competitive Landscape

4.1 Recent developments & impact analysis, by key market participants
- 4.1.1 Ansoff Matrix
4.2 Company Categorization
- 4.2.1 Innovators
  - 4.2.1.1 Market Differentiators
4.3 Vendor Landscape
- 4.3.1 List Of Key Distributors And Channel Partners
- 4.3.2 Key Customers
- 4.3.3 Key Company Market Share Analysis, 2025
4.4 Public Companies
- 4.4.1 Competitive Dashboard Analysis
4.5 Private Companies
- 4.5.1 List Of Key Emerging Companies
4.6 Regional Network Map

Chapter 5. High Potency Active Pharmaceutical Ingredients Market: Segment Analysis, By Product, 2021 - 2033 (USD Million)

5.1 Definition and Scope
5.2 Product Market Share Analysis, 2025 & 2033
5.3 Global High Potency Active Pharmaceutical Ingredients Market, By Product, 2021 To 2033
5.4 High Potency Active Pharmaceutical Ingredients Market: Product Movement Analysis
5.5 Synthetic
- 5.5.1 Synthetic market estimates and forecasts, 2021 - 2033 (USD Million)
5.6 Biotech
- 5.6.1 Biotech market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. High Potency Active Pharmaceutical Ingredients Market: Segment Analysis, By Type of Manufacturer, 2021 - 2033 (USD Million)

6.1 Definition and Scope
6.2 Type of Manufacturer Market Share Analysis, 2025 & 2033
6.3 Global High Potency Active Pharmaceutical Ingredients Market, By Type of Manufacturer, 2021 To 2033
6.4 High Potency Active Pharmaceutical Ingredients Market: Type of Manufacturer Movement Analysis
6.5 In-house
- 6.5.1 In-house market estimates and forecasts, 2021 - 2033 (USD Million)
6.6 Outsourced
- 6.6.1 Outsourced market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. High Potency Active Pharmaceutical Ingredients Market: Segment Analysis, By Drug Type, 2021 - 2033 (USD Million)

7.1 Definition and Scope
7.2 Drug Type Market Share Analysis, 2025 & 2033
7.3 Global High Potency Active Pharmaceutical Ingredients Market, By Drug Type, 2021 To 2033
7.4 High Potency Active Pharmaceutical Ingredients Market: Therapy Movement Analysis
7.5 Innovative
- 7.5.1 Innovative market estimates and forecasts, 2021 - 2033 (USD Million)
7.6 Generic
- 7.6.1 Generic market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 8. High Potency Active Pharmaceutical Ingredients Market: Segment Analysis, By Application, 2021 - 2033 (USD Million)

8.1 Definition and Scope
8.2 Therapy Market Share Analysis, 2025 & 2033
8.3 Global High Potency Active Pharmaceutical Ingredients Market, By Therapy, 2021 To 2033
8.4 High Potency Active Pharmaceutical Ingredients Market: Therapy Movement Analysis
8.5 Oncology
- 8.5.1 Oncology market estimates and forecasts, 2021 - 2033 (USD Million)
8.6 Hormonal Disorders
- 8.6.1 Hormonal disorders market estimates and forecasts, 2021 - 2033 (USD Million)
8.7 Glaucoma
- 8.7.1 Glaucoma market estimates and forecasts, 2021 - 2033 (USD Million)
8.8 Other Therapeutic Applications
- 8.8.1 Other therapeutic applications market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 9. High Potency Active Pharmaceutical Ingredients Market: Regional Business Analysis

9.1 Definition & Scope
9.2 Regional Market Share Analysis, 2025 & 2033
9.3 Regional Market Dashboard
9.4 Regional Market Snapshot
9.5 SWOT Analysis, By Factor (Political & Legal, Economic And Technological)
- 9.5.1 North America
- 9.5.2 Europe
- 9.5.3 Asia Pacific
- 9.5.4 Latin America
- 9.5.5 MEA
9.6 Market Size, & Forecasts, Trend Analysis, 2022 to 2030
9.7 North America
- 9.7.1 North America High Potency Active Pharmaceutical Ingredients Market Estimates And Forecast, 2021 - 2033 (USD Million)
- 9.7.2 U.S.
  - 9.7.2.1 U.S. high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.7.2.2 Key Country Dynamics
  - 9.7.2.3 Regulatory Framework
  - 9.7.2.4 Competitive Scenario
- 9.7.3 Canada
  - 9.7.3.1 Canada high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.7.3.2 Key Country Dynamics
  - 9.7.3.3 Regulatory Framework
  - 9.7.3.4 Competitive Scenario
9.8 Europe
- 9.8.1 Europe High Potency Active Pharmaceutical Ingredients Market, 2021 - 2033 (USD Million)
- 9.8.2 UK
  - 9.8.2.1 UK high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.8.2.2 Key Country Dynamics
  - 9.8.2.3 Regulatory Framework
  - 9.8.2.4 Competitive Scenario
- 9.8.3 Germany
  - 9.8.3.1 Germany high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.8.3.2 Key Country Dynamics
  - 9.8.3.3 Regulatory Framework
  - 9.8.3.4 Competitive Scenario
- 9.8.4 Spain
  - 9.8.4.1 Spain high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.8.4.2 Key Country Dynamics
  - 9.8.4.3 Regulatory Framework
  - 9.8.4.4 Competitive Scenario
- 9.8.5 France
  - 9.8.5.1 France high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.8.5.2 Key Country Dynamics
  - 9.8.5.3 Regulatory Framework
  - 9.8.5.4 Competitive Scenario
- 9.8.6 Italy
  - 9.8.6.1 Italy high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.8.6.2 Key Country Dynamics
  - 9.8.6.3 Regulatory Framework
  - 9.8.6.4 Competitive Scenario
- 9.8.7 Norway
  - 9.8.7.1 Norway high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.8.7.3 Regulatory Framework
  - 9.8.7.4 Competitive Scenario
- 9.8.8 Denmark
  - 9.8.8.1 Denmark high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.8.8.2 Key Country Dynamics
  - 9.8.8.3 Regulatory Framework
  - 9.8.8.4 Competitive Scenario
- 9.8.9 Sweden
  - 9.8.9.1 Sweden high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.8.9.2 Key Country Dynamics
  - 9.8.9.3 Regulatory Framework
  - 9.8.9.4 Competitive Scenario
9.9 Asia Pacific
- 9.9.1 Asia-Pacific High Potency Active Pharmaceutical Ingredients Market, 2021 - 2033 (USD Million)
- 9.9.2 Japan
  - 9.9.2.1 Japan high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.9.2.2 Key Country Dynamics
  - 9.9.2.3 Regulatory Framework
  - 9.9.2.4 Competitive Scenario
- 9.9.3 China
  - 9.9.3.1 China high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.9.3.2 Key Country Dynamics
  - 9.9.3.3 Regulatory Framework
  - 9.9.3.4 Competitive Scenario
- 9.9.4 India
  - 9.9.4.1 India high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.9.4.2 Key Country Dynamics
  - 9.9.4.3 Regulatory Framework
  - 9.9.4.4 Competitive Scenario
- 9.9.5 South Korea
  - 9.9.5.1 South Korea high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.9.5.2 Key Country Dynamics
  - 9.9.5.3 Regulatory Framework
  - 9.9.5.4 Competitive Scenario
- 9.9.6 Thailand
  - 9.9.6.1 Thailand high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.9.6.2 Key Country Dynamics
  - 9.9.6.3 Regulatory Framework
  - 9.9.6.4 Competitive Scenario
- 9.9.7 Australia
  - 9.9.7.1 Australia high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.9.7.2 Key Country Dynamics
  - 9.9.7.3 Regulatory Framework
  - 9.9.7.4 Competitive Scenario
9.10 Latin America
- 9.10.1 Latin America High Potency Active Pharmaceutical Ingredients Market, 2021 - 2033 (USD Million)
- 9.10.2 Brazil
  - 9.10.2.1 Brazil high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.10.2.2 Key Country Dynamics
  - 9.10.2.3 Regulatory Framework
  - 9.10.2.4 Competitive Scenario
- 9.10.3 Mexico
  - 9.10.3.1 Mexico high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.10.3.2 Key Country Dynamics
  - 9.10.3.3 Regulatory Framework
  - 9.10.3.4 Competitive Scenario
- 9.10.4 Argentina
  - 9.10.4.1 Argentina high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.10.4.2 Key Country Dynamics
  - 9.10.4.3 Regulatory Framework
  - 9.10.4.4 Competitive Scenario
9.11 MEA
- 9.11.1 MEA High Potency Active Pharmaceutical Ingredients Market, 2021 - 2033 (USD Million)
- 9.11.2 South Africa
  - 9.11.2.1 South Africa high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.11.2.2 Key Country Dynamics
  - 9.11.2.3 Regulatory Framework
  - 9.11.2.4 Competitive Scenario
- 9.11.3 Saudi Arabia
  - 9.11.3.1 Saudi Arabia high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.11.3.2 Key Country Dynamics
  - 9.11.3.3 Regulatory Framework
  - 9.11.3.4 Competitive Scenario
- 9.11.4 UAE
  - 9.11.4.1 UAE high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.11.4.2 Key Country Dynamics
  - 9.11.4.3 Regulatory Framework
  - 9.11.4.4 Competitive Scenario
- 9.11.5 Kuwait
  - 9.11.5.1 Kuwait high potency active pharmaceutical ingredients market, 2021 - 2033 (USD Million)
  - 9.11.5.2 Key Country Dynamics
  - 9.11.5.3 Regulatory Framework
  - 9.11.5.4 Competitive Scenario

Chapter 10. High Potency Active Pharmaceutical Ingredients Market: Company Profiles

10.1 Company Profiles
- 10.1.1 BASF SE
  - 10.1.1.1 Company Overview
  - 10.1.1.2 Financial Performance
  - 10.1.1.3 Product Benchmarking
  - 10.1.1.4 Strategic Initiatives
- 10.1.2 CordenPharma International
  - 10.1.2.1 Company Overview
  - 10.1.2.3 Strategic Initiatives
- 10.1.3 Bristol-Myers Squibb Company
  - 10.1.3.1 Company Overview
  - 10.1.3.2 Financial Performance
  - 10.1.3.3 Product Benchmarking
  - 10.1.3.4 Strategic Initiatives
- 10.1.4 Carbogen Amcis AG
  - 10.1.4.1 Company Overview
  - 10.1.4.2 Financial Performance
  - 10.1.4.3 Product Benchmarking
  - 10.1.4.4 Strategic Initiatives
- 10.1.5 Pfizer Inc.
  - 10.1.5.1 Company Overview
  - 10.1.5.2 Financial Performance
  - 10.1.5.3 Product Benchmarking
  - 10.1.5.4 Strategic Initiatives
- 10.1.6 Boehringer Ingelheim International GmbH
  - 10.1.6.1 Company Overview
  - 10.1.6.2 Financial Performance
  - 10.1.6.3 Product Benchmarking
  - 10.1.6.4 Strategic Initiatives
- 10.1.7 Dr. Reddy's Laboratories Ltd.
  - 10.1.7.1 Company Overview
  - 10.1.7.2 Financial Performance
  - 10.1.7.3 Product Benchmarking
  - 10.1.7.4 Strategic Initiatives
- 10.1.8 Sun Pharmaceutical Industries, Ltd.
  - 10.1.8.1 Company Overview
  - 10.1.8.2 Product Benchmarking
  - 10.1.8.3 Strategic Initiatives
- 10.1.9 Albany Molecular Research, Inc.
  - 10.1.9.1 Company Overview
  - 10.1.9.2 Financial Performance
  - 10.1.9.3 Product Benchmarking
  - 10.1.9.4 Strategic Initiatives
- 10.1.10 Sanofi
  - 10.1.10.1 Company Overview
  - 10.1.10.2 Financial Performance
  - 10.1.10.3 Product Benchmarking
  - 10.1.10.4 Strategic Initiatives
- 10.1.11 Cipla Inc.
  - 10.1.11.1 Company Overview
  - 10.1.11.2 Financial Performance
  - 10.1.11.3 Product Benchmarking
  - 10.1.11.4 Strategic Initiatives

한글목차

HPAPI 시장 요약

목차

제1장 HPAPI 시장 : 조사 방법과 범위

제2장 HPAPI 시장 : 개요

제3장 HPAPI 시장 : 변수, 동향, 범위

제4장 HPAPI 시장 : 경쟁 구도

제5장 HPAPI 시장 부문 분석 : 제품별, 2021-2033년

제6장 HPAPI 시장 부문 분석 : 제조업체 유형별, 2021-2033년

제7장 HPAPI 시장 부문 분석 : 약제 유형별, 2021-2033년

제8장 HPAPI 시장 부문 분석 : 용도별, 2021-2033년

제9장 HPAPI 시장 부문 분석 : 지역별 비즈니스 분석

제10장 HPAPI 시장 : 기업 개요